Month: August 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland and Boston, MA – August 22, 2022 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing novel therapies to improve women’s reproductive health, today announced that on August 19, 2022 it received a notification letter from The Nasdaq Stock Market (“Nasdaq”) advising the Company that it was not in compliance with Listing Rule 5450(b)(1)(A) requiring companies listed on the Nasdaq Global Select Market to maintain a minimum of $10,000,000 in stockholders’ equity for continued listing. The notification letter from Nasdaq was based on the Company’s Form 6-K dated August 17, 2022, disclosing financial information for the period ended June 30, 2022, which reported shareholders’ equity of ($2,103,000). Under Nasdaq rules the Company...

Moses Lake, Washington USA August 22, 2022: The passage of the Inflation Reduction Act which includes SEMA legislation will drive increases in the U.S. production of polysilicon and metallurgical grade silicon. REC Silicon and Mississippi Silicon today announce a Memorandum of Understanding committing the companies to negotiate a raw material supply agreement and help establish a low-carbon and fully traceable U.S.-based solar supply chain. Recent investment by the Hanwha Group into REC Silicon, in conjunction with Hanwha’s subsidiary Qcells, moves REC to expand its relationship with Mississippi Silicon to support the development of an end-to-end U.S. solar supply chain from raw silicon, to polysilicon, and finally fully assembled modules. Passage of Senator Jon Ossoff’s Solar Energy Manufacturing for America Act as part of a broad clean...

Pratteln, Switzerland, and Rockville, MD, USA, August 22, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the first patient has been dosed in a Phase 2 pilot study to assess vamorolone in Becker muscular dystrophy (BMD), funded by the U.S. Food and Drug Administration (FDA). This Phase 2 pilot study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and exploratory clinical efficacy on motor function outcomes of vamorolone compared to placebo over a treatment period of 24 weeks in 39 males (aged ≥18 and

KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanisms Phase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoing Interim data from Phase 2 study in hospitalized COVID-19 patients expected end of Q3 Webinar on Aug 24 starts at 2:00 pm CET (8:00 am ET)Basel, Switzerland, 22 August 2022 — Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, today announced it will host a virtual event on the use of KIN001 for the treatment of COVID-19 on Wednesday, August 24 at 2:00 pm CET. The webinar will feature a presentation by Dr. Thierry Fumeaux M.D., MBA, Chief Medical Officer of Kinarus and former Chairman of the Swiss National COVID-19 Scientific Task...

OSLO, Norway, Aug. 22, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website: https://nykode.com/investors/financial-reports-and-presentations/. About Nykode TherapeuticsNykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and infectious diseases. Nykode’s modular vaccine technology specifically targets antigens...